GH Research PLC (GHRS) Reports 73% Remission in Phase 2b Depression Trial
GH Research PLC (NASDAQ:GHRS) is a clinical-stage biopharmaceutical company developing innovative therapies for treatment-resistant depression (TRD) and other psychiatric and neurological disorders.






